Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891362708> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2891362708 abstract "e21006 Background: IPI (anti-CTLA4) is approved for treatment of advanced MEL in adults, and more information on efficacy and safety of IPI in younger patients (pts) is needed. Methods: Pts from study CA184-178 (NCT01696045) age 12 to <18 yrs with previously treated or untreated, unresectable stage III or IV malignant MEL received up to 4 doses of IPI at 3 or 10 mg/kg Q3W. Key exclusion criteria were ocular MEL, active brain metastases, or autoimmune disease. Primary endpoints were 1-yr overall survival (OS) and safety. Results: From April 2013 to June 2016, 12 pts received either IPI 3 mg/kg (n=4) or 10 mg/kg (n=8); 2 did not meet study criteria and were not treated. For the 3 and 10 mg/kg groups, median age was 13 yrs and 15 yrs, 50% and 63% were male, 25% and 13% had elevated baseline lactate dehydrogenase, and 75% and 50% had prior systemic therapy, respectively. Median number of IPI doses received was 4.0 (range: 2–4) for 3 mg/kg and 3.0 (range: 1–4) for 10 mg/kg. At 1 yr, 3/4 pts on 3 mg/kg and 5/8 pts on 10 mg/kg were alive (Table). Two pts on 10 mg/kg had partial response and 1 pt from each group had stable disease (Table). One pt had ongoing partial response >2 yrs without further treatment. Treatment-related grade 1-4 adverse events were reported in 2/4 and 7/8 pts in 3 and 10 mg/kg groups, respectively. There was 1 grade 3-4 immune-mediated adverse reaction with 3 mg/kg (hepatitis) and 5 with 10 mg/kg (hepatitis [2] and pyrexia [2] were most common). The study was stopped early due to slow accrual. Conclusions: At >1 yr of follow-up, IPI demonstrated activity in MEL pts aged 12 to <18 yrs, with a safety profile consistent with that observed in adults. Our trial highlights the difficulties of enrolling children with rare diseases in clinical trials for drugs that are approved in adults, suggesting adolescents should be included earlier in adult trials of promising new drugs. Clinical trial information: NCT01696045. [Table: see text]" @default.
- W2891362708 created "2018-09-27" @default.
- W2891362708 creator A5011494265 @default.
- W2891362708 creator A5034237316 @default.
- W2891362708 creator A5037169725 @default.
- W2891362708 creator A5046880941 @default.
- W2891362708 creator A5048381166 @default.
- W2891362708 creator A5051922909 @default.
- W2891362708 creator A5052068446 @default.
- W2891362708 creator A5054595403 @default.
- W2891362708 creator A5060067333 @default.
- W2891362708 creator A5061565715 @default.
- W2891362708 creator A5068118481 @default.
- W2891362708 creator A5085328645 @default.
- W2891362708 creator A5086018137 @default.
- W2891362708 date "2017-05-20" @default.
- W2891362708 modified "2023-09-24" @default.
- W2891362708 title "Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL)." @default.
- W2891362708 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e21006" @default.
- W2891362708 hasPublicationYear "2017" @default.
- W2891362708 type Work @default.
- W2891362708 sameAs 2891362708 @default.
- W2891362708 citedByCount "1" @default.
- W2891362708 countsByYear W28913627082018 @default.
- W2891362708 crossrefType "journal-article" @default.
- W2891362708 hasAuthorship W2891362708A5011494265 @default.
- W2891362708 hasAuthorship W2891362708A5034237316 @default.
- W2891362708 hasAuthorship W2891362708A5037169725 @default.
- W2891362708 hasAuthorship W2891362708A5046880941 @default.
- W2891362708 hasAuthorship W2891362708A5048381166 @default.
- W2891362708 hasAuthorship W2891362708A5051922909 @default.
- W2891362708 hasAuthorship W2891362708A5052068446 @default.
- W2891362708 hasAuthorship W2891362708A5054595403 @default.
- W2891362708 hasAuthorship W2891362708A5060067333 @default.
- W2891362708 hasAuthorship W2891362708A5061565715 @default.
- W2891362708 hasAuthorship W2891362708A5068118481 @default.
- W2891362708 hasAuthorship W2891362708A5085328645 @default.
- W2891362708 hasAuthorship W2891362708A5086018137 @default.
- W2891362708 hasConcept C121608353 @default.
- W2891362708 hasConcept C126322002 @default.
- W2891362708 hasConcept C141071460 @default.
- W2891362708 hasConcept C146357865 @default.
- W2891362708 hasConcept C151730666 @default.
- W2891362708 hasConcept C2777701055 @default.
- W2891362708 hasConcept C2781433595 @default.
- W2891362708 hasConcept C71924100 @default.
- W2891362708 hasConcept C86803240 @default.
- W2891362708 hasConcept C90924648 @default.
- W2891362708 hasConceptScore W2891362708C121608353 @default.
- W2891362708 hasConceptScore W2891362708C126322002 @default.
- W2891362708 hasConceptScore W2891362708C141071460 @default.
- W2891362708 hasConceptScore W2891362708C146357865 @default.
- W2891362708 hasConceptScore W2891362708C151730666 @default.
- W2891362708 hasConceptScore W2891362708C2777701055 @default.
- W2891362708 hasConceptScore W2891362708C2781433595 @default.
- W2891362708 hasConceptScore W2891362708C71924100 @default.
- W2891362708 hasConceptScore W2891362708C86803240 @default.
- W2891362708 hasConceptScore W2891362708C90924648 @default.
- W2891362708 hasLocation W28913627081 @default.
- W2891362708 hasOpenAccess W2891362708 @default.
- W2891362708 hasPrimaryLocation W28913627081 @default.
- W2891362708 hasRelatedWork W1984022925 @default.
- W2891362708 hasRelatedWork W2037880959 @default.
- W2891362708 hasRelatedWork W2095826876 @default.
- W2891362708 hasRelatedWork W2211219919 @default.
- W2891362708 hasRelatedWork W2245837981 @default.
- W2891362708 hasRelatedWork W2252676806 @default.
- W2891362708 hasRelatedWork W2466257091 @default.
- W2891362708 hasRelatedWork W2494386866 @default.
- W2891362708 hasRelatedWork W2553511888 @default.
- W2891362708 hasRelatedWork W2585928802 @default.
- W2891362708 hasRelatedWork W2588270636 @default.
- W2891362708 hasRelatedWork W2590729007 @default.
- W2891362708 hasRelatedWork W2598944313 @default.
- W2891362708 hasRelatedWork W2602986569 @default.
- W2891362708 hasRelatedWork W2603690292 @default.
- W2891362708 hasRelatedWork W2890466450 @default.
- W2891362708 hasRelatedWork W2979984046 @default.
- W2891362708 hasRelatedWork W3006202513 @default.
- W2891362708 hasRelatedWork W3033241570 @default.
- W2891362708 hasRelatedWork W3094017079 @default.
- W2891362708 isParatext "false" @default.
- W2891362708 isRetracted "false" @default.
- W2891362708 magId "2891362708" @default.
- W2891362708 workType "article" @default.